These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 24743778)

  • 1. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.
    Xiong A; Yang Z; Shen Y; Zhou J; Shen Q
    Cancers (Basel); 2014 Apr; 6(2):926-57. PubMed ID: 24743778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 transcription factor as target for anti-cancer therapy.
    Mohassab AM; Hassan HA; Abdelhamid D; Abdel-Aziz M
    Pharmacol Rep; 2020 Oct; 72(5):1101-1124. PubMed ID: 32880101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.
    Siveen KS; Sikka S; Surana R; Dai X; Zhang J; Kumar AP; Tan BK; Sethi G; Bishayee A
    Biochim Biophys Acta; 2014 Apr; 1845(2):136-54. PubMed ID: 24388873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting transcription factor STAT3 for cancer prevention and therapy.
    Chai EZ; Shanmugam MK; Arfuso F; Dharmarajan A; Wang C; Kumar AP; Samy RP; Lim LH; Wang L; Goh BC; Ahn KS; Hui KM; Sethi G
    Pharmacol Ther; 2016 Jun; 162():86-97. PubMed ID: 26478441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.
    Wang W; Lopez McDonald MC; Hariprasad R; Hamilton T; Frank DA
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.
    Germain D; Frank DA
    Clin Cancer Res; 2007 Oct; 13(19):5665-9. PubMed ID: 17908954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT proteins: novel molecular targets for cancer drug discovery.
    Turkson J; Jove R
    Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
    Beebe JD; Liu JY; Zhang JT
    Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT proteins as novel targets for cancer drug discovery.
    Turkson J
    Expert Opin Ther Targets; 2004 Oct; 8(5):409-22. PubMed ID: 15469392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer.
    Mali SB
    Oral Oncol; 2015 Jun; 51(6):565-9. PubMed ID: 25817923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting STAT3 in Cancer with Nucleotide Therapeutics.
    Lau YK; Ramaiyer M; Johnson DE; Grandis JR
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
    Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y
    Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 the oncogene - still eluding therapy?
    Wake MS; Watson CJ
    FEBS J; 2015 Jul; 282(14):2600-11. PubMed ID: 25825152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?
    Masuda M; Wakasaki T; Suzui M; Toh S; Joe AK; Weinstein IB
    Curr Cancer Drug Targets; 2010 Feb; 10(1):117-26. PubMed ID: 20088788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical analysis of the potential for targeting STAT3 in human malignancy.
    Peyser ND; Grandis JR
    Onco Targets Ther; 2013; 6():999-1010. PubMed ID: 23935373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.
    Nikitakis NG; Siavash H; Sauk JJ
    Curr Cancer Drug Targets; 2004 Dec; 4(8):637-51. PubMed ID: 15578920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
    Tan FH; Putoczki TL; Stylli SS; Luwor RB
    Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-1299 is a negative regulator of STAT3 in colon cancer.
    Wang Y; Lu Z; Wang N; Zhang M; Zeng X; Zhao W
    Oncol Rep; 2017 Jun; 37(6):3227-3234. PubMed ID: 28498395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.